Management of Patients with Diabetes in the Peri-operative Period



Section A – General Principles

1.0 Key points

- 1.1 Target capillary blood glucose reading (CBG) throughout an admission is 6 to 12mmol/l.
- 1.2 Low or high CBG readings MUST be managed promptly. Information from this guidance can be used as a reference, taking into account patient variation factors. Specialist advice from the Diabetes team should be sought especially for management of complex cases.
- 1.3 Patients should be involved in the peri-operative management of their diabetes. This can be initiated in the Pre-Assessment Clinic. A key aspect to good peri-operative diabetes management is an early and robust management plan in the pre-assessment period.
- 1.4 A HbA1c reading should be obtained within 3 months of the planned surgery to assess glycaemic control. Pre-operative management of patients with HbA1c ≥ 69mmol/mol should be discussed with the Diabetes team or an anaesthetist. Consideration should be given to optimise diabetic control by referring to the patient's GP or the Diabetes team ideally within this time period. Patients with suboptimally controlled diabetes undergoing emergency/urgent procedures (where there is insufficient time to optimise control) should be highlighted to the Diabetes team as soon as possible.
- 1.5 Patients with diabetes should be prioritised for surgery whenever possible (*eg: placed first on the list*).
- 1.6 Not all patients require a variable rate intravenous insulin infusion (VRIII) previously known as a sliding scale. Patients undergoing a short fast (likely to miss only one meal) can be managed by modifications of their medications. See guidance in 'Section A point 4.0' and 'Section B' for more information.
- 1.7 Diabetic patients who are initiated on artificial feeding (TPN, NG, NJ, RIG feeding etc) should have a management plan discussed with the Diabetes Team when feeding starts.

2.0 Capillary blood glucose (CBG) testing

- 2.1 Test CBG at least four times a day in the peri-operative period for all patients with diabetes (including diet-controlled).
- 2.2 During the fasting period, test CBG every 2 hours.
- 2.3 Record of CBG is also recommended in the following stages:
 - a. Just before start of procedure
 - b. Just after completion of procedure
 - c. At least once when in recovery
 - d. On arrival back to ward
- 2.4 A higher frequency of testing may be required if the patient's blood glucose or CBG is labile.
- 2.5 Test immediately if the patient is displaying signs and symptoms of hypo- or hyperglycaemia and treat accordingly as per local guidance.
- 2.6 Patients on a VRIII should have hourly CBG readings. Reduce to 2 hourly if CBG readings remain stable for 4 hours, with no insulin infusion rate changes.

3.0 Patients using continuous subcutaneous insulin infusion (CSII) pumps at home

- 3.1 Management of patients with CSII pumps should be discussed with the Diabetes team at the earliest opportunity.
- 3.2 CSII pumps should be stopped and disconnected in the following patients:
 - a. Critically unwell
 - b. Undergoing major surgery
 - c. Unable to self-manage CSII pump independently
 - d. Undergoing radiological procedures
 - e. Patients who do not have supply of own consumables eg. infusion sets
- 3.3 If the pump is likely to be disconnected for more than 1 hour, ensure an alternative source of insulin is started a VRIII is a suitable option unless otherwise advised by the Diabetes team.
- 3.4 Prolonged disconnection of a CSII pump will result in DKA unless alternative insulin is given.
- 3.5 Inpatient guidance on CSII pumps can be found on the 'Edinburgh Centre for Endocrinology and Diabetes' website: <u>http://www.edinburghdiabetes.com/</u>

4.0 Management of diabetic medications in the fasting period

- 4.1 For emergency cases, it is likely that more than one meal will be missed. Attempt to get an estimate of the time of procedure (morning or afternoon). Start VRIII unless it is certain that only 1 meal will be missed. Please discuss with anaesthetic team performing individual assessments (if applicable).
- 4.2 For bowel surgery, patients may continue to have little to no oral intake. Use of VRIII may be appropriate for 48 hours post-procedure. For cases where this is likely to continue beyond 48 hours, please contact Diabetes team for specialist advice for ongoing management.

INSULINS								
Туре	Day before	Day of o	peration	Advice if VRII is being used				
	operation	Morning operation	Afternoon operation					
Long acting insulin	Take as	Restart at usual	Restart at usual	Continue at 80% of usual dose				
(taken in the evening)	normal*	dose when eating.	dose when eating.	when VRIII is in use. When VRIII is stopped restart 100% of usual dose.				
eg: Lantus, Levemir, Tresiba, Insulatard, Humulin I								
Long acting insulin	Take as	Take as normal*	Take as normal*	Continue at 80% of usual dose				
(taken in the	normal*			when VRIII is in use. When VRIII				
morning)				is stopped restart 100% of usual dose.				
eg: Lantus, Levemir, Tresiba, Insulatard, Humulin I								
*Reduction to 80%	of dose of long a	ncting insulin on day be	fore operation should	be considered in patients with				
		-		rnight. This may include patients				
on large doses of lo	ng acting insulir	n to account for oral in	take.					
Mix insulin	Take as	Continue at 50% of	Continue at 50% of	Stop when VRIII is in use.				
	normal	usual dose in the	usual dose in the	Restart when eating and				
eg: Novomix 30,		morning.	morning.	drinking. Dose may vary if oral				
Humalog Mix 25,				intake is reduced compared to				
Humulin M3		Restart at usual	Restart at usual	normal oral intake.				
		dose when eating.	dose when eating.					
				*If > 1 missed meal, stop mix				
				insulin and start VRIII.				
For twice daily long insulin.	acting insulin (e	eg: Lantus, Levemir, In	sulatard, Humulin I) p	lease follow guidance for mix				
Short acting	Take as	Stop	Take morning dose	Stop when VRIII is in use.				
insulin	normal		with breakfast then	Restart when eating and				
		Restart when	stop.	drinking. Dose may vary if oral				
eg: Novorapid,		eating. Consider		intake is reduced.				
Actrapid, Apidra,		adjusting dose if	Restart when					
Humalog		oral intake is	eating. Dose may	*If > 1 missed meal, stop short				
		reduced.	vary if oral intake is reduced.	acting insulin and start VRIII.				

operation Morning operation Afternoon operation Metformin* Take as normal Stop Stop Stop when VRIII is in use "If >1 missed meal, stop start VRIII / CBG persiste >14mmol/. *Metformin may be withheld 24 hours before and 48 hours after procedure involving contrast. Consider withholding when concens with renal injury and infection. Stop SGLT-2 inhibitor Stop ** Stop Stop eg: empagliforin, dapogliforin, dapogliforin, dapogliforin, dapogliforin, dapogliforin, dapogliforin, dapogliforin, dapogliforin **For patients with poorly controlled diabetes (hbA1c >69mmol/mol) and at risk of development, both and is adequately hydrated. Please contact Diabetes team for advice if alternat. blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) Take as normal Take as normal. Take as normal. Stop eg: glicazide, glibenciamide, glibenciamide, glibenciamide, glimepiride Take as normal If taken once a day in the morning, omit dose. Stop when VRIII is in use. Thiazolidinediones Take as normal Take as normal. Take as normal. Stop when VRIII is in use. </th <th>Туре</th> <th colspan="7">Day before Day of operation Advice if VRII is being use</th>	Туре	Day before Day of operation Advice if VRII is being use								
Metformin* Take as normal Stop Stop Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/L. *Metformin may be withheld 24 hours before and 48 hours after procedure involving contrast. Consider withholding when concerns with renal injury and infection. Stop ** Stop Stop Stop SGLT-2 inhibitor acroagifizin, depoglifizin, canagifizin **For patients with poorly controlled diabetes (HbA1c >69mmol/Mol) and trisk of dehydration, stop at least 3 days before procedure. Do not restart until patient is eat well and is adequately hydrated. Please contact Diabetes team for advice if alternat blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased Tikelihood of deterioration of the patient's hydration status. Continued use of SCHT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) Take as normal Take as normal. Take as normal. Stop subplontide, glibencianide, glibencianide, glimepiride Take as normal If taken once a day if taken twice a day, omit dose. Stop when VRIII is in use. Thiazolidinediones Take as normal Take as normal. Take as normal. Stop when VRIII is in use. eg: ploglitazone Take as normal Take as normal. Take as normal. Stop when V		operation	Morning	Afternoon						
normal **If >1 missed meal, stop start VRIII if CBC persiste >14mmol/L **Metformin may be withheld 24 hours before and 48 hours ofter procedure involving contrast. Consider withholding when concerns with renal injury and infection. SGLT-2 inhibitor eg: empaglifozin, dapaglifozin, dapaglifozin, dapaglifozin, dapaglifozin Stop* Stop Stop **For patients with poorly controlled diabetes (HbALc >65mmol/mol) and at risk of dehydration, stop at least 3 days before procedure. Do not restart until patient is ead well and is adequately hydrated. Please contact Diabetes team for advice if alternat blood glucose control required. SGLT-2 inhibitors surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) eg: exendide, dialogluide, dialogluide, dialogluide, gilmepiride Take as normal If taken once a day in the morning, omit dose. Stop when VRIII is in use in the morning, omit dose. Stop when VRIII is in use *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. Thiazolidinediones g: ploglitazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. Thiazolidinediones g: repaglinide, nateglinide Take as normal. Take as normal. Take as normal. Take as normal. Stop when VRIII is in use *			operation	operation						
*Metformin may be withheld 24 hours before and 48 hours after procedure involving contrast. Consider withholding when concerns with renal injury and infection. SGLT-2 inhibitor eg: empagiljozin, danagiljozin **For patients with poorly controlled diabetes (HbA1c >66mmol/mol) and at risk of dehydration, stop at least 3 days before procedure. Do not restart until patient is eat well and is adequately hydrated. Please contact Diabetes team for advice if alternate blood glucose control required. SGLT-2 inhibitors SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis. GLP-1 analogue Take as normal. Take as normal. Take as normal. eg: exenatide, tiragluide, dualquitide, emagluide Take as normal. If taken once a day in the morning, omit dose. Stop when VRIII is in use. Sulphonylureas eg: gliciaide, glimepinde Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. Thiazolidinediones Take as normal. Take as normal. Do not restart until eatin dose. Stop when VRIII is in use. gg: gliciaide, glimepinde Take as normal. Take as normal. Take as normal. Do not restart until eatin dose. Thiazolidinediones Take as normal. Take a	Metformin*	Take as	Stop	Stop	Stop when VRIII is in use.					
SGLT-2 Inhibitor Stop Stop Stop searchilde Stop Stop Stop Stop Stop searchilde Stop		normal								
SGLT-2 inhibitor Stop** Stop Stop seq: empagificzin, danagificzin **For patients with poorly controlled diabetes (HbA1c >69mmol/mol) and at risk of dehydration, stop at least 3 days before procedure. Do not restart until patient is eat well and is adequately hydrated. Please contact Diabetes team for advice if alternate blood glucose control required. SGLT-2 inhibitor SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. Stop GLP-1 analogue Take as normal. Take as normal. Take as normal. in the morning, glibenclamide, normal Take as normal. If taken twice a day, omit morning day, omit morning. Stop when VRIII is in use "If >1 missed meal, stop start VRIII if CBG persiste >14mmol/I.										
*Metformin may be withheld 24 hours before and 48 hours after procedure involving contrast. Consider withholding when concerns with renal injury and infection. SGLT-2 inhibitor Stop Stop ge: empaglifatin dapaglifatin dapaglifatin **For patients with poorly controlled diabetes (HbA1c >69mmol/mol) and at risk of dehydration, stop at least 3 days before procedure. Do not restart until patient is ead well and is adequately hydrated. Please contact Diabetes team for advice if alternati- blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. Stop GLP-1 analogue (injectable and oral) eg: exenatide, gilinegluide, guidencide, glibenciamide Take as normal Take as normal. Stop when VRIII is in use normal. Take as normal. Thiazolidinediones eg: proglitazone Take as normal Take as normal. Take as normal. <td></td> <td></td> <td></td> <td></td> <td></td>										
contrast. Consider withholding when concerns with renal injury and infection. SGLT-2 inhibitor Stop Stop eg: empagilfozin, dapogilfozin, canaglifozin **For patients with poorly controlled diabetes (HbA1c >69mmol/mol) and at risk of dehydration, stop at least 3 days before procedure. Do not restart until patient is eat well and is a dequately hydrated. Please contact Diabetes team for advice if alternate blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) Take as normal Take as normal. Take as normal. eg: exenatide, ilroglutide, dulaglutide, dulaglutide, glimepiride Take as normal If taken nonce a day in the morning, omit dose. Stop when VRIII is in use. eg: gliclazide, glimepiride Take as normal If taken twice a day, omit morning dose. If taken twice a day, omit both dose. Stop when VRIII is in use. Take as normal Take as normal. Take as normal. Stop when VRIII is in use. Pipplightazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. eg: repaglinide, nateglinide Take as normal <td></td> <td></td> <td></td> <td></td> <td></td>										
SGLT-2 inhibitor Stop** Stop Stop eg: empaglifozin, dapoglifozin, dapoglifozin **For patients with poorly controlled diabetes (HbA1c >69mmol/mol) and at risk of dehydration, stop at least 3 days before procedure. Do not restart until patient is eat well and is adequately hydrated. Please contact Diabetes team for advice if alternati- blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. Stop GLP-1 analogue (injectable and oral) eg: exenatide, ingedutide, dulaglutide, get exenatide, glibenclamide, glibenclamide, glimepinde Take as normal Take as normal. Take as normal. Stop Thiazolidinediones ge: pioglitazone Take as normal If taken once a day in the morning, omit dose. If taken twice a day, omit both doses. Stop when VRIII is in use. Thiazolidinediones ge: pioglitazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. Take as normal Take as normal. Take as normal. Take as normal. Take as normal. Thiazolidinediones g: pioglitazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. <tr< td=""><td></td><td colspan="8"></td></tr<>										
eg: empaglifozin, dapoglifozin, canaglifozin eargeigliozin **For patients with poorly controlled diabetes (HbA1c >69mmol/mol) and at risk of dehydration, stop at least 3 days before procedure. Do not restart until patient is eat well and is adequately hydrated. Please contact Diabetes team for advice if alternate blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) reg: exenatide, irraglutide, dualguitide, gg: gliclazide, glibenclamide, gg: gliclazide, glimepiride Thiazolidinediones eg: pioglitazone reg: pioglitazone reg: pioglitazone reg: repaglinide, normal Take as normal Take as normal Take as normal Take as normal Take as normal Take as normal Take as normal Take as normal. Take as normal. Ta										
dapaglifozin, canaglifozin **For patients with poorly controlled diabetes (HbA1c >69mm0/mol) and at risk of dehydration, stop at least 3 days before procedure. Do not restart until patient is eat well and is adequately hydrated. Please contact Diabetes team for advice if alternate blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) Take as normal Take as normal. Take as normal. eg: exenatide, liregluide, dualgluide, glibenclamide, glibenclamide, glibenclamide, glibenclamide, glimepiride Take as normal If taken once a day in the morning, omit dose. If taken once a day in the morning, omit dose. Stop when VRIII is in use. in the morning, omit dose. Do not restart until eating. Take as normal If taken twice a day, omit morning dose. Stop when VRIII is in use. in the as normal. Stop when VRIII is in use. in the morning, omit dose. Thiazolidinediones eg: pioglitzzone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. in ormal. Take as normal Take as normal. Take as normal. Stop when VRIII is in use. in the morning if eating. Thiazolidinediones eg: pioglifizzone Take as normal. Take in the morning if eating	SGLI-2 Inhibitor	Stop	stop	Stop	Stop					
dehydration, stop at least 3 days before procedure. Do not restart until patient is ent well and is adequately hydrated. Please contact Diabetes team for advice if alternate blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) eg: exenatide, lingalutide, dulagitide, glibenclamide, glimepiride Take as normal Take as normal. Take as normal. Stop For patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may offect intestinal motility. If taken once a day in the morning, omit dose. If taken once a day in the morning, omit dose. Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. Thiazolidinediones eg: pioglitozone Take as normal Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMS persiste >14mmol/l. Meglitnide eg: repaglinide, nateglinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. DPP-IV inhibitor parterionin Take as normal. Take as normal. Stop when VRIII is in use. *If >1 missed meal, stop start VRIII is in use. *If >1 missed meal, stop start VRIII i		**		l diabataa (Ub A1a > CO	ward at rick of					
well and is adequately hydrated. Please contact Diabetes team for advice if alternat. blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) Take as normal Take as normal. Take as normal. eg: exenatide, lireglutide, dulaglutide, semaglutide Take as normal Take as normal. Stop For patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may affect intestinal motility. Stop when VRIII is in use. in the morning, omit dose. Stop when VRIII is in use. in the morning, omit dose. gilibenclamide, gilimepiride Take as normal If taken once a day in the morning dose. If taken twice a day, omit morning dose. Stop when VRIII is in use. 'If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. Thiazolidinediones eg: pioglitazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. 'If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l. Meglitinide eg: repaglinide, nateglinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. 'If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. DPP-IV inhibitor Take										
blood glucose control required. SGLT-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) Take as normal Take as normal. Stop eg: exenatide, liraglutide, semaglutide For patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may affect intestinal motility. Stop when VRIII is in use. in the morning, omit dose. Stop when VRIII is in use. in the morning, omit dose. eg: gliclazide, glimepiride Take as normal If taken once a day in the morning, omit dose. Stop when VRIII is in use. in the morning, omit dose. Thiazolidinediones eg: pioglitazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. 'If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. Meglitinide eg: pioglitazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. 'If >1 missed meal, stop start VRIII if BMS persiste >14mmol/l. Meglitinide eg: repaglinide, nateglinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. 'If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. DPP-IV inhibitor Take as normal Take as norm	canaglifozin									
SGL7-2 inhibitors MUST be withheld in acute serious illnesses and where emergency surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGL7-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) Take as normal. Take as normal. Take as normal. eg: exenatide, liraglutide, semaglutide Take as normal. Take as normal. If taken once a day in the morning, omit dose. Stop when VRIII is in use. SUlphonylureas iglibenclamide, glimepiride Take as normal. If taken once a day in the morning, omit dose. If taken twice a day, omit morning dose. Stop when VRIII is in use. Thiazolidinediones eg: pioglitazone Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. mormal Take as normal. Take as normal. Do not restart until eating. Do not restart until eating. Thiazolidinediones eg: repaglinide, nateglinide Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste start VRIII if CBG persiste sta										
surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis.GLP-1 analogue (injectable and oral)Take as normalTake as normal.Stopeg: exenatide, uiraglutide, dulaglutide, ger glicazide, glibenclamide, mormalTake as normal.If taken once a day in the morning, omit dose. If taken twice a day, omit both doses.Stop when VRIII is in use. start VRIII is in use. Take as normal.Take as normalTake as normal.Take as normal.Take as normal.Take as normal.Take as normalTake as normal.Take as normal.Take in the morning if eating. <td></td> <td></td> <td>control i cyun cui</td> <td></td> <td></td>			control i cyun cui							
surgery is indicated due to the increased likelihood of deterioration of the patient's hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis.GLP-1 analogue (injectable and oral)Take as normalTake as normal.Stopeg: exenatide, uiraglutide, dulaglutide, ger glicazide, glibenclamide, mormalTake as normal.If taken once a day in the morning, omit dose. If taken twice a day, omit both doses.Stop when VRIII is in use. start VRIII is in use. Take as normal.Take as normalTake as normal.Take as normal.Take as normal.Take as normal.Take as normalTake as normal.Take as normal.Take in the morning if eating. <td></td> <td>SGLT-2 inhibito</td> <td>ors MUST be withheld</td> <td>in acute serious illness</td> <td>ses and where emergency</td>		SGLT-2 inhibito	ors MUST be withheld	in acute serious illness	ses and where emergency					
hydration status. Continued use of SGLT-2 inhibitors in these situations may lead to ketoacidosis, including euglycaemic ketoacidosis. GLP-1 analogue (injectable and oral) Take as normal Take as normal. Stop eg: exenatide, lirgulutide, semaglutide Take as normal Take as normal. Take as normal. Stop For patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may affect intestinal motility. If taken once a day in the morning, omit dose. If taken once a day in the morning, omit dose. Stop when VRIII is in use. Sulphonylureas eg: gliclazide, glibenclamide, glimepiride Take as normal If taken twice a day, omit morning dose. If taken twice a day, omit both doses. Stop when VRIII is in use. *If >1 missed meal, stop start VRII if CBG persiste >14mmol/l. Thiazolidinediones eg: pioglitazone Take as normal Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. Meglitinide eg: repaglinide, nateglinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. DPP-IV inhibitor Take as normal Take as normal. Take as normal. Take as normal. Stop when VRIII is in use.										
GLP-1 analogue (injectable and oral) Take as normal Take as normal. Take as normal. Stop eg: exenatide, diaglutide, dulaglutide, semaglutide For patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may affect intestinal motility. For patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may affect intestinal motility. Sulphonylureas eg: gliclazide, glibenclamide, glibenclamide, glimepiride Take as normal If taken once a day in the morning, omit dose. If taken twice a day, omit morning dose. Stop when VRIII is in use. Do not restart until eating. If taken twice a day, omit morning dose. If taken twice a day, omit both dose. Stop when VRIII is in use. Thiazolidinediones eg: pioglitazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. Meglitinide eg: repaglinide, nateglinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. DPP-IV inhibitor Take as normal Take as normal. Take as normal. Take as normal. Stop when VRIII is in use.										
For patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may affect intestinal motility.For patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may affect intestinal motility.Sulphonylureas eg: gliclazide, glimepirideTake as normalIf taken once a day in the morning, omit dose.If taken once a day in the morning, omit dose.Stop when VRIII is in use. "If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.Thiazolidinediones eg: pioglitazoneTake as normalTake as normalTake as normal.Do not restart until eating.Do not restart until eating.Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.Take as normal.Stop when VRIII is in use. "If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake in the morning if eating.Stop when VRIII is in use. "If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.DPP-IV inhibitor en: sitaglintinTake as normalTake as normal.Take as normal.Take as normal.DPP-IV inhibitor en: sitaglintinTake as normalTake as normal.Take as normal.Stop when VRIII is in use. "If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.		ketoacidosis, i	ncluding euglycaemic l	ketoacidosis.						
eg: exenatide, liraglutide, aulaglutide, semaglutideFor patients undergoing bowel surgery, do not restart until patient is eating well. GL analogues may affect intestinal motility.Sulphonylureas eg: gliclazide, glibenclamide, glimepirideTake as normalIf taken once a day in the morning, omit dose.If taken once a day in the morning, omit dose.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14 mmol/l.Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.If take as normal.Take as normal.Tage: repaglinide, nateglinideTake as normalTake as normal.Take as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14 mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMS persiste >14 mmol/l.DPP-IV inhibitor eg: sitaglintinTake as normalStopTake in the morning if eating.*If >1 missed meal, stop start VRIII is in use. *If >1 missed meal, stop start VRIII is in use. >>14 mmol/l. <br< td=""><td>-</td><td>Take as</td><td>Take as normal.</td><td>Take as normal.</td><td>Stop</td></br<>	-	Take as	Take as normal.	Take as normal.	Stop					
Inraglutide, dulaglutide, semaglutide For patients in argeny offect integrand potential graph, both relationed in the patient is calling when cell analogues may affect intestinal motility. Sulphonylureas eg: gliclazide, glibenclamide, glimepiride Take as normal If taken once a day in the morning, omit dose. If taken once a day in the morning, omit dose. Stop when VRIII is in use. If taken twice a day, omit morning dose. If taken twice a day, omit morning dose. If taken twice a day, omit both doses. Stop when VRIII is in use. Thiazolidinediones eg: pioglitazone Take as normal Take as normal Take as normal. Stop when VRIII is in use. Meglitinide eg: repaglinide, nateglinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. PPP-IV inhibitor Take as normal Stop Take as normal. Stop when VRIII is in use. ee: sitaglintin Take as normal Take as normal. Take as normal. Stop when VRIII is in use.	(injectable and oral)	normal								
Inraglutide, dulaglutide, semaglutide For patients in argeny offect integrand potential graph, both relationed in the patient is calling when cell analogues may affect intestinal motility. Sulphonylureas eg: gliclazide, glibenclamide, glimepiride Take as normal If taken once a day in the morning, omit dose. If taken once a day in the morning, omit dose. Stop when VRIII is in use. If taken twice a day, omit morning dose. If taken twice a day, omit morning dose. If taken twice a day, omit both doses. Stop when VRIII is in use. Thiazolidinediones eg: pioglitazone Take as normal Take as normal Take as normal. Stop when VRIII is in use. Meglitinide eg: repaglinide, nateglinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. PPP-IV inhibitor Take as normal Stop Take as normal. Stop when VRIII is in use. ee: sitaglintin Take as normal Take as normal. Take as normal. Stop when VRIII is in use.	agi avangtida									
dulaglutide, semaglutide anthogues may affect intestment motility. Sulphonylureas Take as normal If taken once a day in the morning, omit dose. If taken once a day in the morning, omit dose. Stop when VRIII is in use. glimepiride If taken twice a day, omit morning dose. If taken twice a day, omit both doses. If taken twice a day, omit both doses. If taken twice a day, omit both doses. Stop when VRIII is in use. Thiazolidinediones eg: pioglitazone Take as normal Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. eg: pioglitazone Take as normal Take as normal. Take as normal. Stop when VRIII is in use. eg: repaglinide, nateglinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. DPP-IV inhibitor Take as normal Take as normal. Take as normal. Stop when VRIII is in use. eg: sitanglintin Take as normal Take as normal. Take in the morning if eating. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.	-	-			l patient is eating well. GLP-1					
eg: gliclazide, glibenclamide, glimepiridenormalin the morning, omit dose.in the morning, onit dose.in the morning, on trestart until eating.in the morning, on not restart until eating.in the morning, on not restart until eating.in the morning, on start VRIII is in use.in the morning, if sit was normal.in the morning, if sit was normal.in the morning, on start VRIII is in use.in the morning, if sit was normal.in the morning, on start VRIII is in use.in	dulaglutide,	analogues mag	y affect intestinal moti	lity.						
eg: gliclazide, glibenclamide, glimepiridenormalin the morning, omit dose.in the morning, onit dose.in the morning, on trestart until eating.in the morning, on not restart until eating.in the morning, on not restart until eating.in the morning, if an inseed meal, stop start VRIII if CBG persiste >14 mmol/l.in the morning, on not restart until eating.in the morning, if an inseed meal, stop start VRIII if CBG persiste >14 mmol/l.Do not restart until eating.DPP	semaglutide									
eg: gliclazide, glibenclamide, glimepirideomit dose.omit dose.*If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.If taken twice a day, omit morning dose.If taken twice a day, omit both dose.If taken twice a day, omit both doses.If taken twice a day, omit both doses.>14mmol/l.Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.Take as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake in the morning if eating.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.DPP-IV inhibitor eq: sitaulintinTake as normalTake as normal.Take as normal.Stop when VRIII is in use. morning if eating.DPP-IV inhibitor eq: sitaulintinTake as normalTake as normal.Take as normal.Stop when VRIII is in use.	Sulphonylureas	Take as			Stop when VRIII is in use.					
glibenclamide, glimepirideomit dose.omit dose.omit dose.omit dose.omit dose.omit dose.omit dose.off >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.glimepirideIf taken twice a day, omit morning dose.If taken twice a day, omit morning dose.If taken twice a day, omit both doses.If taken twice a day, omit both doses.>14mmol/l.Do not restart until eating.Do not restart until eating.Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.Take as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake in the morning if eating.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.DPP-IV inhibitor ea: sitaglintinTake as normalTake as normal.Take as normal.Take as normal.	ea: aliclazide	normal	•	U .						
If taken twice a day, omit morning dose.If taken twice a day, omit both doses.If taken twice a day, omit both doses.>14mmol/l.Do not restart until eating.Do not restart until eating.No not restart until eating.Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.Take as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake in the morning if eating.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.DPP-IV inhibitor eg: sitaglintinTake as normalTake as normal.Take as normal.Take as normal.			omit dose.	omit dose.						
day, omit morning dose.day, omit both doses.Do not restart until eatingDo not restart until eating.Do not restart until eating.Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.Take as normal.Take as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake in the morning if eating.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.DPP-IV inhibitor eg: sitaglintinTake as normalTake as normal.Take as normal.Take as normal.	glimepiride									
dose. doses. Do not restart until eating. Thiazolidinediones Take as normal. Take as normal. Do not restart until eating. Thiazolidinediones Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. eg: pioglitazone Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. Meglitinide Take as normal. Take in the normal Stop Take in the morning if eating. Stop when VRIII is in use. eg: repaglinide, nateglinide Take as normal. Take as normal. Take in the morning if eating. Stop when VRIII is in use. DPP-IV inhibitor Take as normal. Take as normal. Take as normal. Take as normal. Stop when VRIII is in use. eg: sitaglintin. Take as normal. Take as normal. Stop when VRIII is in use.					>14mmol/I.					
Do not restart until eating.Do not restart until eating.Do not restart until eating.Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.Take as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake in the morning if eating.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.DPP-IV inhibitor eg: sitaglintin normalTake as normalTake as normal.Take as normal.Take as normal.										
Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.Take as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake in the morning if eating.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.DPP-IV inhibitor eq: sitaglintinTake as normalTake as normal.Take as normal.Take as normal.			dose.	doses.	Do not restart until eating.					
Thiazolidinediones eg: pioglitazoneTake as normalTake as normal.Take as normal.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l.Meglitinide eg: repaglinide, nateglinideTake as normalStopTake in the morning if eating.Stop when VRIII is in use. *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l.DPP-IV inhibitor eg: sitaglintinTake as normalTake as normal.Take as normal.Take as normal.			Do not restart until	Do not restart until						
Thiazolidinediones Take as normal Take as normal. Take as normal. Stop when VRIII is in use. eg: pioglitazone normal Take as normal. Take as normal. Take as normal. *If >1 missed meal, stop start VRIII if BMs persiste >14mmol/l. Meglitinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. eg: repaglinide, nateglinide normal Stop Take in the morning if eating. *If >1 missed meal, stop start VRIII if CBG persister >14mmol/l. DPP-IV inhibitor Take as normal. Take as normal. Take as normal. Take as normal. eg: sitaglintin Take as normal. Take as normal. Take as normal. Stop when VRIII is in use.										
eg: pioglitazone normal *If >1 missed meal, stop start VRIII if BMs persister >14mmol/l. Meglitinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. eg: repaglinide, nateglinide normal Stop Take as normal. *If >1 missed meal, stop start VRIII is in use. DPP-IV inhibitor Take as normal. Take as normal. Take as normal. Take as normal.	Thiazolidinediones	Take as	-	-	Stop when VRIII is in use.					
Meglitinide Take as Stop Take in the Stop when VRIII is in use. eg: repaglinide, normal Stop Take in the Stop when VRIII is in use. nateglinide Take as Stop Take in the *If >1 missed meal, stop DPP-IV inhibitor Take as Take as normal. Take as normal. Take as normal.										
Meglitinide Take as Stop Take in the Stop when VRIII is in use. eg: repaglinide, normal Stop Take in the Stop when VRIII is in use. nateglinide Normal Stop Take in the Stop when VRIII is in use. DPP-IV inhibitor Take as Take as normal. Take as normal. Take as normal.	eg: pioglitazone				*If >1 missed meal, stop and					
Meglitinide Take as normal Stop Take in the morning if eating. Stop when VRIII is in use. eg: repaglinide, nateglinide normal Stop Take in the morning if eating. *If >1 missed meal, stop start VRIII if CBG persister >14mmol/l. DPP-IV inhibitor Take as normal Take as normal. Take as normal. Stop when VRIII is in use.					start VRIII if BMs persistently					
eg: repaglinide, nateglinide normal morning if eating. *If >1 missed meal, stop start VRIII if CBG persister >14mmol/I. DPP-IV inhibitor Take as normal Take as normal. Take as normal.					>14mmol/l.					
eg: repaginide, *If >1 missed meal, stop nateglinide start VRIII if CBG persister >14mmol/l. Do not restart until eatin DPP-IV inhibitor Take as normal. normal Take as normal.	Meglitinide	Take as	Stop		Stop when VRIII is in use.					
nateglinide *If >1 missed meal, stop start VRIII if CBG persiste >14mmol/l. Do not restart until eatin Do not restart until eatin DPP-IV inhibitor Take as normal. Take as normal. normal Take as normal. Stop when VRIII is in use.	ea: rengalinide	normal		morning if eating.						
DPP-IV inhibitor Take as normal. Take as normal. Stop when VRIII is in use.					*If >1 missed meal, stop and					
DPP-IV inhibitor Take as normal. Take as normal. Stop when VRIII is in use.					start VRIII if CBG persistently					
DPP-IV inhibitorTake as normalTake as normal.Take as normal.Stop when VRIII is in use.ea: sitaglintinnormal					>14mmol/l.					
DPP-IV inhibitorTake as normalTake as normal.Take as normal.Stop when VRIII is in use.ea: sitaglintinnormal					Do not roctort until the					
ea: sitaglintin		Taka	Taka as as as	Teke er mennel						
ea' sitaalintin	UPP-IV INNIBITOR		Take as normal.	Take as normal.	Stop when VKIII is in use.					
TIT NI MICCOM MODEL CTOR		nonnai			*If >1 missed meal, stop and					
start VPUL if CPC persists					start VRIII if CBG persistently					
vildagliptin, alogliptin start vRITI CBG persister >14mmol/l.										

5.0 Post-Operative Care

- 5.1 A carefully documented plan post-procedure is vital.
- 5.2 Restart regular diabetic medication at their normal administration times once the patient is eating.
- 5.3 VRIII should be stopped when the patient is able to maintain good oral intake. Allow an overlap of at least 30 to 60 minutes with regular diabetic medication before stopping VRIII.
- 5.4 Doses of insulin and oral medications may need to be adjusted to compensate for any reduction in carbohydrate intake or stress-induced hypo or hyperglycaemia. If unsure, please discuss with a senior clinician or the Diabetes team for specialist advice.
- 5.5 Restart a patient's CSII pump as soon as the patient starts eating and drinking normally and allow an overlap of at least 1 hour before stopping VRIII. Do not recommence CSII at bedtime.
- 5.6 A VRIII may be appropriate for patients on enteral feeding or total parenteral nutrition (TPN) in the short term, but a SC insulin regimen is preferable. Please discuss with the Diabetes team for specialist advice prior to commencing artificial feeding. Information on the patient's diabetes treatment, CBG readings and total carbohydrate in enteral feed or TPN bags will assist in consultation.

VRIII use may lead to hypo- or hyperglycaemia and ketosis on cessation. It can also cause hyponatraemia due to large volume of fluid delivery. These risks are exacerbated by prolonged use. Please seek advice from the Diabetes team when the duration extends beyond 48 hours.

1.0 Indications for a VRIII

- 1.1 The following groups of patients require a VRIII:
 - a. Fasting patients with Type 1 Diabetes missing more than one meal or if background insulin has not been given
 - b. Fasting patients with insulin dependent Type 2 Diabetes missing more than one meal
 - c. Fasting patients with Type 2 Diabetes with CBG consistently above 14mmol/l
 - d. Patients on CSII with the pump disconnected prior to surgery
 - e. Patients on the emergency list who are likely to miss >1 meal
 - f. Patients who have little to no oral intake post-procedure due to gut rest or post-operative complications (eg: post-operative ileus)
- 1.2 VRIII may be initiated on the ward or in theatre pre-procedure.

2.0 Prescription

- 2.1 A total of 50units of Actrapid (0.5ml of 100units/ml) should be added to 49.5ml of sodium chloride 0.9% to make a final concentration of 1unit/ml.
- 2.2 Administer insulin via an infusion pump into the same cannula as the substrate fluid through a non-return valve.
- 2.3 Long acting insulin (eg: Levemir, Lantus, Tresiba) should be continued at 80% of normal dose with VRIII.

3.0 Substrate fluid with VRIII

- 3.1 When making a prescription of substrate fluid, please indicate clearly that this fluid is for VRIII on fluid chart.
- 3.2 The substrate fluid of choice for most patients is glucose 4% and sodium chloride 0.18% with potassium chloride 40mmol in 1000ml.
- 3.3 In Neurosurgery, the substrate fluid of choice is glucose 5% and sodium chloride 0.45% with potassium chloride 20mmol in 500ml.
- 3.4 If potassium level is greater than 5.0mmol/L omit potassium in the substrate fluid.
- 3.5 Addition of potassium in substrate fluid is not required for patients with end stage renal disease or patients on renal replacement therapy. Discuss with senior medical staff or Diabetes team if uncertain.
- 3.6 Monitor serum electrolytes at least once daily to guide the need for additional electrolyte replacement.
- 3.7 The rate of the infusion is determined by the patient's weight as described on the IV fluid chart. The patient's fluid status and clinical condition should also be considered.
- 3.8 For patients with hyponatraemia (sodium <131mmol/l), an increase in sodium content of the infusion substrate fluid will be required at a combined rate suitable for the patient's requirements. Please consult anaesthetist or senior medical staff for advice.

4.0 Management of VRIII

- 4.1 Monitor CBG hourly, reducing to 2 hourly if CBG is consistently within 6 to 12mmol/l, with no insulin infusion rate changes.
- 4.2 Rate of infusion should be initiated as per prescription chart, using the most appropriate scale as described on the chart.
- 4.3 Patients with Type 2 diabetes frequently require more insulin. For persistent hyperglycaemia (three consecutive CBG readings >12mmol/l without a 3mmol/l/hr drop), increase the maximum VRIII rate by 1unit/hr (eg: switch from scale 2 to scale 3 on the VRIII prescription chart). Several rate increments may be required.
- 4.4 Insulin <u>should not</u> be infused without a substrate fluid (i.e. IV fluid containing glucose) outwith Critical Care areas. This could lead to **severe hypoglycaemia**.

5.0 VRIII for patients at risk of fluid overload

- 5.1 Please discuss ongoing use of VRIII in patients with fluid overload with a senior member of staff or seek specialist advice from Diabetes team. Running VRIII for prolonged periods may lead to fluid overload or hyponatraemia. A daily check of urea and electrolytes is mandatory to avoid electrolyte imbalance.
- 5.2 The rate of the substrate fluid typically lies between 50 to 100ml/hr. Depending on the patient's CBG, the rate can be reduced if fluid overload is a concern but caution must be exercised to avoid hypoglycaemia.
- 5.3 Consider using glucose 10% with potassium chloride 10mmol as a substrate fluid for patients at risk of fluid overload (eg: patients with heart failure or renal disease) to limit the amount of substrate fluid required to maintain target CBG.
- 5.4 If potassium level is greater than 5.0mmol/l omit potassium in the substrate fluid.

6.0 Stopping the VRIII

- 6.1 The VRIII should be discontinued once the patient is ready to eat and drink at a mealtime without significant nausea or vomiting.
- 6.2 Commence the patient's normal diabetes medication(s) with a meal. This includes oral and SC insulin. The dose of SC insulin may need to be adjusted to compensate for reduced carbohydrate intake. If unsure, please discuss a suitable dose with the patient or the Diabetes team.
- 6.3 An overlapping period of 30 to 60 minutes is required after the patient's regular insulin has been administered before the VRIII is stopped as the half-life of IV insulin is extremely short.
- 6.4 For patients with Type 1 diabetes, ensure the patient's basal insulin has been administered prior to discontinuation of VRIII.
- 6.5 Hypo- or hyperglycaemia is possible after discontinuation of a VRIII. The patient's CBG should be checked regularly and treatment initiated as per recommended guidance in Section C. Seek specialist advice from the Diabetes team if required.

Section C – Management of Hypo or Hyperglycaemic Episode

1.0 Hypoglycaemia

For management of hypoglycaemia (CBG <4mmol/l) please follow Lothian guidance on management of hypoglycaemia. Guidance can be found on the 'Edinburgh Centre for Endocrinology and Diabetes' website: <u>http://www.edinburghdiabetes.com/</u>

2.0 Hyperglycaemia

For management of hyperglycaemia (persistent CBG above recommended target range) please seek specialist advice from Diabetes team.

References:

1. Management of adults with diabetes undergoing surgery and elective procedures: Improving standards (revised march 2016), Joint British Diabetes Societies (JBDS) for inpatient care.

Peri-operative diabetes management interest group:

- Jin Hah, Lead Pharmacist Surgery WGH
- Dr Stuart Ritchie, Consultant Endocrinologist and Diabetologist WGH
- Dr Scott MacKenzie, Consultant Endocrinologist and Diabetologist RIE
- Dr Radzi Noh, Consultant Physician SJH
- Katharine Ramage, Diabetes Specialist Nurse WGH
- Dr Simon Heaney, Consultant Anaesthetist RIE
- Dr Morag Renton, Consultant Anaesthetist SJH
- Dr Susan Rae, Consultant Anaesthetist WGH
- Dr Debbie Morley, Consultant Anaesthetist WGH
- Dr Keith Kelly, Consultant Anaesthetist DCN RIE
- Nicole Cromar, Lead Pharmacist DCN RIE

Variable Rate Intravenous Insulin Infusion (VRIII) PRESCRIPTION CHART

Ward: ______ Site: _____ Date: _____

VRIII is a continuous infusion and is made up of : 50units (0.5ml) soluble insulin (Actrapid) in

49.5ml sodium chloride 0.9% (1ml = 1unit Actrapid)

Addressograph or		
Name:		
Address:		
DOB:		
Unit no. :	CHI:	

Medicine	Total Dose	Infusion Fluid	Final Concentration	Route	Prescribed by (sign & print)
Actrapid	50units	Sodium Chloride 0.9%	50units in 50ml	IV	

Prescribe one of the insulin infusion scales below:

- Scale 1 should be considered for insulin-sensitive patients, those on less than 24units of insulin per day (eg: elderly or low BMI patients with type 1 diabetes).
- Scale 2 is suitable for most patients.
- Scale 3 will better suit insulin resistant patients, typically high BMI patients with type 2 diabetes who take a total of over 100 units of insulin per day.
- Do not stop long-acting insulins (eg: Levemir, Lantus, Tresiba) when starting VRIII. Continue at 80% of usual dose. Remember to review the dose again once VRIII has stopped.

Capillary blood glucose (mmol/l)	Scale 1 For Insulin sensitive patients	Scale 2 Standard Rate for most patients	Scale 3 For insulin resistant patients	Scale 4 Custom scale			
	Rate (Units/hr)	Rate (Units/hr)	Rate (Units/hr)	Rate (Units/hr)			
Less than 4.0	Nil (Treat Hypo)	Nil (Treat Hypo)	Nil (Treat Hypo)				
4.0 - 8.0	0.5	1	2				
8.1 - 12.0	1	2	4				
12.1 - 16.0	2	4	6				
16.1 - 20.0	3	5	7				
20.1 - 24.0	4	6	8				
More than 24.0	6	8	10				
Prescriber:							
Prescriber to sign and print name under the selected scale. Score through scales which are not to be used							

Prescriber to sign and print name under the selected scale. Score through scales which are not to be used.

- Prescribe 1000ml glucose 4% and sodium chloride 0.18% with potassium chloride 40mmol as substrate fluid except in Neurosurgery where 500ml glucose 5% and sodium chloride 0.45% with potassium chloride 20mmol should be used instead. Indicate clearly on fluid chart that this fluid prescription is <u>for VRIII</u>.
- The rate of the infusion is determined by the patient's weight and should match their daily fluid requirement.
- Measure serum electrolytes at least once daily to guide sodium and potassium replacement. If potassium level is greater than 5.0mmol/l, omit potassium in the substrate fluid.
- Administer the insulin via an infusion pump into the same IV cannula as the substrate fluid, through a non-return valve.

						Addressograph or					
NH	S Va	Variable Rate Intravenous Insulin				Addressograph or					
	🔰 Inf	Infusion (VRIII)			Nar	Name:					
Lathian					Add	ress:					
MONITORING CHART											
			_		DO	. .					
Ward: _		Site:	Da	ate:							
					Un	t no. :		CHI:			
•		apillary Blood	•	• •							
•	Regular r 12mmol/I		/ of the in	sulin infusio	n rates is e	ssential to e	nsure good	glycaemic	control (CBG of 6-		
•		of scale or cust									
•				-					the patient without		
									30 to 60minutes.		
A	В	С	D	E	F Volume	G	Н		J		
Date	Time (24hr clock)	Blood glucose (mmol/L)	Rate ml/hr	Volume (ml) remaining in syringe	(ml) infused since last check	Total volume (ml) infused (calculated	Total volume (ml) infused – device	Initials (2 to set up / change	Cannula check and Comments		
					(calculated from E)	from E)	reading	rate)			
					, , , , , , , , , , , , , , , , , , ,						

Written by: Peri-operative diabetes management interest group Approved by: NHS Lothian Drugs and Therapeutics Committee Date: March 2021 Review date: March 2023